DiaUnion at the 5th Childhood Diabetes Prevention Symposium

Last week FDA approved the teplizumab drug (Tzield™) that has delayed the onset of type 1 diabetes (T1D) for up 7 years in clinical trials for people at risk for developing T1D.

This makes it urgent to establish an infrastructure for detection of people at risk for developing T1D, which is exactly what DiaUnion is doing.

Watch the video of DiaUnion PI Daniel Agardh’s presentation at the 5th Childhood Diabetes Prevention Symposium earlier this month: